Tesamorelin tracker
Educational reference for Tesamorelin. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
0.4 h
Tmax
0.25 h
Category
peptide
Also known as: Egrifta, TH9507
> PLACEHOLDER — pending clinical review by licensed pharmacist. Tesamorelin is an FDA-approved GHRH analog (Egrifta) used to reduce visceral fat in HIV-associated lipodystrophy. Subcutaneous injection.
Mechanism
A stabilized GHRH analog that stimulates the GHRH receptor to promote growth-hormone release. It is the most clinically developed GHRH analog in this catalog.
Research summary
FDA-approved (as Egrifta) to reduce excess abdominal fat in people with HIV-associated lipodystrophy, based on clinical trials. Research has also explored other metabolic contexts. Use outside the approved indication is not supported by that approval.
Dosing in the literature
Approved-product administration is subcutaneous under a prescribing clinician. Specific regimens are individualized and outside the scope of this summary.
Reported side effects
Reported effects include injection-site reactions, joint pain, and fluid retention. Prescribing information notes considerations such as effects on glucose tolerance and IGF-1 monitoring, and contraindications. This is not a complete safety profile.
Stacking notes
Combination use is a clinical decision; effects on glucose metabolism and IGF-1 are relevant monitoring considerations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Tesamorelin trials in HIV-associated lipodystrophy · peer-reviewed clinical trials (2010)search PubMed for tesamorelin lipodystrophy
- Egrifta prescribing information · FDA prescribing information (2010)available via DailyMed / accessdata.fda.gov
Track Tesamorelin in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.